Connecting Scientific Ecosystems to Boston’s Biotech Infrastructure
A Boston-based venture capital firm with a structured, repeatable model to engineer biotech assets from discovery to global pharma relevance.
"This fund is the result of years of disciplined work by Dreavent to build a model that connects scientific ecosystems to Boston's biotech infrastructure in a structured, repeatable way. It demonstrates that with the right methodology and a team with deep experience investing in and building biotech assets from inside the world's leading pharma companies and venture funds, that bridge can be engineered — not just envisioned. Spain is the first market. The model is designed to scale."
Gorka Fius — Founder & Managing Partner, Dreavent Capital Management
THE DREAVENT ADVANTAGE
A Differentiated Model
Most biotech funds evaluate scientific potential and hope for pharmaceutical interest. Dreavent inverts this logic. We start with confirmed pharmaceutical demand, identifying what large pharma companies need in their pipelines, and work backwards to find the science that can address it. Every asset we invest in has a confirmed pharmaceutical partner engaged before capital is deployed. This is not deal flow. It is Bio Asset Engineering.
Institutional Investment Team
Dreavent's Investment Committee has operated at the highest level of pharmaceutical venture capital, from inside the corporate venture arms of the world's leading pharma companies to Tier 1 biotech funds. They have built, evaluated, and exited assets across the full spectrum of biotech development, with a combined track record of dozens of investments and multiple landmark exits including acquisitions by major global pharmaceutical companies. They bring not just capital judgment but direct pharma relationships, which is what makes the Bio Asset Engineering model executable.
Boston/Cambridge at the Center
Boston is the world's most efficient biotech development ecosystem, where the BD and R&D decision-makers of every major pharmaceutical company, the deepest pool of specialized life sciences capital, and the talent that has navigated the FDA pathway repeatedly all coexist. Dreavent is based in Boston and uses it as the permanent development hub for every scientific ecosystem it connects. For portfolio companies, this means direct access to the networks, relationships, and infrastructure that turn promising science into globally competitive pharma assets.
Innovation - Systematic Intelligence
The Dreavent Engine provides a continuous, AI-powered view of the global biotech landscape, mapping therapeutic areas by indication, target, modality, and competitive density; tracking biomarker and endpoint validations from FDA and EMA in real time; evaluating the probability of success of each candidate program across four layers of biological and regulatory risk; and monitoring investment activity from leading pharma CVCs and top-tier biotech funds. This intelligence is available to both the investment team and portfolio companies, ensuring that every decision is grounded in the most current view of the market.
Latest News
April 13, 2026
Dreavent is participating in the Spain–United States Business Summit, held this week in Boston. Organized by ICEX and the Economic and Commercial Offices of the Spanish Embassy in the United States, the Summit brings together business and institutional leaders from both countries with a special focus on innovation, life sciences, and the Boston ecosystem.
April 13, 2026
Dreavent has received a Letter of Intent from the Spanish Government, through COFIDES via its FIEX instrument, committing up to $57M as anchor investor in Dreavent's Spain–Boston fund. This commitment marks a foundational milestone for the launch of a $200M transatlantic investment vehicle designed to connect Spain's scientific base with Boston's biotech infrastructure.